Phase 2 Trial Of S-531011 With RadScopal In Previously Treated Metastatic Colorectal Cancer
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorM.D. Anderson Cancer Center
About this trial
To learn if the experimental drug S-531011 plus RadScopalTM radiation therapy can help to control previously treated metastatic colorectal cancer.
Eligibility criteria
Qualifiers
Age ≥18 years
Histologically or cytologically confirmed non-MSI-H colorectal adenocarcinoma with metastatic or locally advanced unresectable disease.
Anticipated life expectancy greater than 3 months.
Prior receipt of fluoropyrimidine, oxaliplatin, and irinotecan as standard-of-care chemotherapy.
Disqualifiers
Prior treatment with an anti-CCR8 antibody.
Tumor occupying >80% of total liver volume, as assessed by the investigator and/or treating radiation oncologist.
Prior XRT to the target lesion(s) selected for HD-XRT.
Prior organ or tissue allograft.
Trial design
Treatments tested in this trial
- S-531011
- HD-XRT
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov